In mouse and rat models of rheumatoid arthritis, tofacitinib (a selective JAK1/3 inhibitor) administered at initial symptom onset blocked further inflammation and subsequent local joint destruction (including that caused by both bone erosion and cartilage damage)31–33 and reduced RANKL expression in arthritic rat joints32. This evidence concerns the gene JAK1 and rheumatoid arthritis.